Intranasal
From Pepperpedia, the free peptide encyclopedia
Intranasal
Properties
| Category | Glossary |
|---|---|
| Also known as | IN, Intranasal Definition, Nasal Administration, Nasal Spray |
| Last updated | 2026-04-13 |
| Reading time | 3 min read |
| Tags | glossaryadministrationterminologynasal |
Definition
Intranasal (abbreviated IN) is an administration route in which a substance is delivered into the nasal cavity, where it is absorbed through the nasal mucosa into systemic circulation or, for certain compounds, directly into the central nervous system. In peptide research, intranasal delivery is notable for its non-invasive nature and its potential to bypass the blood-brain barrier.
The term derives from the Latin intra- (within) and nasus (nose).
Anatomical Basis
The nasal cavity provides a large, highly vascularized mucosal surface for absorption. Two regions are of particular pharmacological interest:
- Respiratory epithelium — lines most of the nasal cavity and provides access to systemic circulation through a dense submucosal capillary plexus. Substances absorbed here enter the bloodstream similarly to other mucosal routes.
- Olfactory epithelium — located at the roof of the nasal cavity, this region is unique because olfactory nerve fibers penetrate the cribriform plate to connect directly with the olfactory bulb in the brain. Substances deposited on the olfactory epithelium may travel along these nerve pathways to reach the central nervous system, bypassing the blood-brain barrier.
This nose-to-brain pathway is a major area of interest for neuropeptide research.
Advantages for Peptide Delivery
- Non-invasive — no needles required, improving acceptability and ease of self-administration
- Avoidance of first-pass metabolism — substances absorbed through the nasal mucosa enter systemic circulation without passing through the liver, avoiding hepatic degradation
- Potential CNS access — the olfactory pathway offers a route to the brain for peptides that would otherwise be excluded by the blood-brain barrier
- Rapid onset — the rich vascular supply of the nasal mucosa allows quick absorption
- Convenient for neurotropic peptides — compounds like selank, semax, and oxytocin are commonly administered intranasally in research contexts
Limitations
- Variable bioavailability — nasal absorption efficiency varies widely depending on the peptide's molecular weight, lipophilicity, and formulation. Many peptides have nasal bioavailability below 10-20%
- Mucociliary clearance — the nasal cavity continuously produces mucus that is swept toward the nasopharynx by ciliated epithelial cells, limiting the contact time of applied substances
- Enzymatic degradation — the nasal mucosa contains proteolytic enzymes that can degrade peptides before absorption
- Volume limitation — the nasal cavity can retain only 100-200 microliters per nostril; excess volume drains into the throat and is swallowed
- Nasal congestion — inflammation, allergies, or infections can significantly impair absorption
Delivery Devices
Intranasal peptide delivery typically employs:
- Metered-dose spray pumps — deliver a consistent volume per actuation (typically 50-100 microliters), commonly used for desmopressin, oxytocin, and similar peptides
- Dropper bottles — less precise but simple to use
- Specialized devices — certain delivery systems target the olfactory region specifically to maximize nose-to-brain transport
A detailed guide to intranasal technique is available in the Intranasal Administration methods article.
Related Terms
- Intranasal Administration — procedural guide for nasal peptide delivery
- Blood-Brain Barrier — the selective membrane that intranasal delivery may bypass
- Bioavailability — the fraction of peptide reaching systemic circulation
- First-Pass Metabolism — hepatic degradation avoided by intranasal absorption
- Subcutaneous — the most common alternative injection-based route
Related entries
- Bioavailability— The percentage of an administered compound that reaches systemic circulation in its active form, heavily influenced by the route of administration.
- Blood-Brain Barrier— The highly selective semipermeable membrane that separates circulating blood from the brain extracellular fluid, presenting a major challenge for delivering peptide therapeutics to the central nervous system.
- Intramuscular— A glossary definition of intramuscular as it applies to peptide administration — injection directly into skeletal muscle tissue for systemic absorption.
- Subcutaneous— A glossary definition of subcutaneous as it applies to peptide administration — the tissue layer beneath the skin and above the muscle where most peptide injections are deposited.
- Intranasal Administration— A needle-free method of delivering peptides through the nasal mucosa, offering rapid absorption and potential direct access to the central nervous system, though with variable bioavailability and dosing challenges.